Is it Always Safe to Administer RAS Inhibitors to Patients Who Underwent Unilateral Radical Nephrectomy?

Area of Science:

• Nephrology
• Oncology
• Pharmacology

Background:

• Unilateral nephrectomy typically triggers compensatory increases in single-kidney glomerular filtration rate (GFR).
• The impact of hemodynamically active medications on early post-nephrectomy GFR compensation is not well understood.
• Atherosclerotic nephropathy and diabetes can affect renal reserve and recovery potential.

Purpose of the Study:

• To investigate the effect of combined ACE and SGLT2 inhibition on early GFR compensation after unilateral radical nephrectomy.
• To explore potential hemodynamic mechanisms by which these therapies might influence renal recovery.
• To highlight the importance of individualized perioperative management in patients with compromised renal function.

Main Methods:

• Case report of a 65-year-old male with clear cell renal cell carcinoma undergoing radical nephrectomy.
• Preoperative assessment of split renal function and baseline GFR.
• Monitoring of GFR at 3 months post-surgery during combined ramipril and dapagliflozin therapy.
• Evaluation of GFR changes after discontinuation of ramipril and dapagliflozin.

Main Results:

• Post-nephrectomy GFR remained suboptimal despite continued ramipril and dapagliflozin treatment.
• Following discontinuation of both agents, GFR increased significantly and stabilized.
• No significant albuminuria was detected during the follow-up period.

Conclusions:

• Combined ACE and SGLT2 inhibition may transiently attenuate early GFR compensation after unilateral nephrectomy, particularly in patients with atherosclerotic nephropathy.
• Hemodynamic effects of these medications might play a role in this observed phenomenon.
• Individualized perioperative medication management and vigilant renal function monitoring are crucial for optimizing outcomes.